Business Context and Reporting Period
This Form 6-K filing by Oculis Holding AG, dated August 10, 2026, reports the entry into an asset purchase agreement with Accure Therapeutics S.L. The transaction involves the acquisition of rights to Privosegtor (ACT-01) and an early-stage preclinical neurology drug candidate, ACT-02.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels for the reporting period. The primary financial data relates to the transaction consideration:
- Upfront Cash Payment: $3.8 million (CHF 3.1 million) payable at the first closing.
- Equity Consideration: Up to 2,050,000 Oculis ordinary shares, comprising upfront shares (subject to a 2-year lockup) and earnout shares (vesting on milestones).
- Future Obligations: Assumption of low single-digit percentage royalties to academic institutions; termination of existing milestone and royalty obligations to Accure upon closing.
Material Changes
The filing details a strategic expansion of Oculis's pipeline through the acquisition of two assets. Upon completion of the Privosegtor acquisition, the existing license agreement between Oculis and Accure will terminate, eliminating prior milestone payments and royalty obligations associated with that specific agreement.
Outlook, Risks, and Contingencies
Closing Timeline: The closing for Privosegtor is expected no later than February 28, 2027, and the closing for ACT-02 is expected no later than March 31, 2027.
Conditions Precedent: Both closings are subject to separate conditions. The ACT-02 closing is explicitly dependent on the successful closing of the ACT-01 transaction.
Risks and Contingencies: The transaction is contingent on the satisfaction or waiver of specified closing conditions. The full text of the agreement, containing customary representations, warranties, and indemnification provisions, is expected to be filed with the Annual Report on Form 20-F for the fiscal year ending December 31, 2026.
Investor Verification Checklist
- Verify the satisfaction of conditions precedent for the Privosegtor (ACT-01) closing by February 28, 2027.
- Confirm the valuation and vesting schedule of the 2,050,000 ordinary shares issued to Accure.
- Review the specific terms of the academic institution license agreements to be assumed, including royalty rates and non-commercial use rights.
- Monitor the filing of the full Asset Purchase Agreement in the upcoming Form 20-F for detailed indemnification and covenant terms.